Solara Active Pharma Sciences Limited
SOLARA
Quarterly Score
Showing the latest 12 quarterly points (newest to oldest).
Score context (latest 12 quarters)
Management reaffirmed FY25 guidance with Revenue of ~INR 1,500 crore and EBITDA of INR 260-290 crore, targeting an exit EBITDA run rate of INR 80 crore per quarter. Growth is supported by a new product pipeline estimated at INR 150-200 crore.
Quarter summary
- Management is executing a 'reset' strategy, transitioning from high-volume Ibuprofen production to a high-value multipurpose API mix.
- A successful USFDA inspection at Vizag provides a critical regulatory runway for new product launches and capacity utilization (up to INR 2,500 crore revenue potential).
Rationale
- Gross margins recovered by 10 percentage points to ~51% following a strategic shift to exit low-margin unregulated market sales and focus on regulated markets (75% of sales).
- Prudent balance sheet 'clean-up' with a INR 120 crore provisioning for COVID-19 inventory that lacked freedom to operate, removing a significant overhang for FY25.
Maintained FY25 guidance: Revenue of ₹1,400-1,500 crores; EBITDA of ₹230-260 crores. Guidance implies a Q4 exit EBITDA run rate of 20-22% (₹80-90 crores). Management expects gross margins to return to 48-50% in H2.
Quarter summary
- Execution of a 'Reset Policy' focusing on network optimization, debt reduction, and a shift toward regulated markets (now >75% of revenue).
- Pivoting the underutilized Vizag asset from commodity Ibuprofen production to a multipurpose CRAMS and specialty API flagship facility.
Rationale
- Material balance sheet improvement via debt reduction of ₹160 crores in Q1, driven by an oversubscribed rights issue and ₹40 crores of free cash flow generation from inventory liquidation.
- Credible guidance for FY25 with revenue targeted at ₹1,400-1,500 crores and EBITDA at ₹230-260 crores, representing a significant turnaround from a difficult FY24.
Management maintained FY25 guidance, targeting a Q4 FY25 exit run rate of ₹400 Cr in revenue and ₹80–90 Cr in EBITDA (approx. 20% margin). FY26 growth is expected to be catalyzed by the Vizag plant coming back online in Q1 FY26.
Quarter summary
- Completion of the corporate 'reset' strategy, pivoting the business from volume-chasing to profitable, regulated-market-heavy growth.
- Successful regulatory outcomes including European approvals for two manufacturing sites and US FDA approval for the R&D center.
Rationale
- Material expansion in Gross Margins to 50.5% (up 620 bps YoY/QoQ), representing a historical high driven by a shift toward regulated markets (76% of mix) and niche products like polymers.
- Significant operational turnaround with EBITDA growing 46% QoQ to ₹61 Cr and margins expanding from 11.6% to 17.7% in a single quarter through aggressive cost containment (opex reduced from ~₹135 Cr base to ₹115 Cr).
Revised revenue guidance downward by ₹100 Cr to a range of ₹1,300-1,400 Cr. Maintained annual EBITDA guidance of ₹230-260 Cr despite a ₹10 Cr specific reduction in Q4 EBITDA expectations. Long-term revenue growth projected at low double digits.
Quarter summary
- Management is prioritizing 'operating leverage over revenue volume,' consciously forfeiting market share in commoditized products to protect a 20% EBITDA margin floor.
- Initiated a structural demerger of the CRAMS and polymer-based API business to create a focused, asset-light entity while improving the parent company's return ratios.
Rationale
- Material improvement in balance sheet health with Net Debt/EBITDA reducing from ~6.0x to 2.5x over six quarters; aiming for <1.5x post-demerger.
- Strong gross margin expansion of 500 bps YoY to 55-56%, driven by a strategic pivot away from low-margin price competition in the Ibuprofen segment (34% of revenue).
Management provided a 'muted' outlook rather than firm guidance for FY26, targeting ~10% revenue growth and 15-20% EBITDA growth. They expect to resolve Ibuprofen competitiveness issues by the end of FY26 through new synthesis routes, though regulatory filings for these changes remain a bottleneck.
Quarter summary
- Strategic pivot from 'reset' to 'profitable growth' following a year of disappointing top-line performance caused by structural shifts in the Ibuprofen market.
- Organizational restructuring via the demerger of the CRAMS and polymers business into a new entity, Synthix Global Pharma Solutions Limited, aimed at pushing down ₹200 crores of debt.
Rationale
- Material improvement in margin profile despite top-line headwinds: Gross margins expanded 1,370 bps YoY to 51.5% in FY25, while EBITDA margins swung from negative to 16.5% (up 2,360 bps).
- Significant deleveraging progress: Total debt reduced from ~₹1,000 crores in FY24 to ₹776 crores in FY25, with a visible path to ~₹650 crores by May 2025 following rights issue proceeds.
Maintained FY26 guidance of ~10% topline growth and 15-20% EBITDA growth (implied ₹240-250Cr EBITDA range). Reaffirmed net debt target of sub-₹450 crore by Q1 FY27.
Quarter summary
- The company has officially transitioned from a 'Reset' phase (FY25) to a 'Growth' phase (FY26), focusing on opex leverage and network optimization.
- Strategic de-leveraging is being prioritized through rights issue proceeds (₹113 crore) and operational cash flows (₹31 crore) to hit a target of <₹450 crore net debt by Q1 FY27.
Rationale
- Material improvement in balance sheet strength with a ₹143 crore debt reduction (18% of opening FY26 debt) in a single quarter, bringing Net Debt/EBITDA down to 2.7x with a clear path to <1.0x post-CRAMS spin-off.
- Return to meaningful profitability with the highest PAT in 12 quarters (₹10.5 crore) and a positive EPS of ₹2.5, validating the 'reset' strategy transition toward 'profitable growth'.
Maintained FY26 outlook of 10% revenue growth and 15%-20% EBITDA growth over the FY25 base; management targets an aspirational 20% EBITDA margin by Q4 FY26 and a net debt-to-EBITDA ratio of 1.5x by Q1 FY27.
Quarter summary
- Financials were severely impacted by a 3-4 week unscheduled operational shutdown at the Mangalore plant for facility refurbishment and upgradation.
- Successful regulatory inspections at two major manufacturing sites provide a compliance 'clearance' that supports long-term volume scalability.
Rationale
- EBITDA declined significantly by 39% Q-o-Q to INR 35.2 Crores, with EBITDA margins compressing to 11% due to an unscheduled 4-week shutdown at the Mangalore facility.
- Material liquidity stress is evident as net current liabilities exceed current assets by INR 70 Crores, and Days Payable Outstanding (DPO) is stretched to 120-150 days against a norm of 60-90 days.
Management declined to provide specific FY27 growth guidance until the Ibuprofen strategic review is completed in Q4 FY26. Guidance is maintained for debt reduction to sub-INR 500 Crores by May 2026.
Quarter summary
- Strategic shift to isolate and potentially divest or restructure the commodity Ibuprofen business while focusing on high-margin 'Growth APIs'.
- Mothballing of the Vizag facility with plans to repurpose it into a multipurpose/high-potent API plant to improve utilization.
Rationale
- Severe asset under-recovery in the core Ibuprofen business with utilization at only ~3,000 tons out of a total 12,000-ton capacity (approx. 25-30% utilization).
- Material deterioration in Ibuprofen margins (now at 21% Gross Margin) due to dated technology and intense competitive pricing pressure from new market entrants.
Future Growth Prospects
Story of the Stock - Top Strategies
Business Segments
Community
Share your view anonymously. Comments are public and sorted newest first.
Anonymous post · 1500 characters left